Skip to main content
Watch Insiders
NTLAHealthcare

Intellia Therapeutics Inc (NTLA) Insider Trading

In the last 90 days, 2 Intellia Therapeutics Inc (NTLA) insiders reported no open-market purchases and 2 sales totaling $309,988. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Oct 2, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Oct 2, 2026Michael P DubeVP, Chief Accounting OfficerSale1,864$12.43$23,170
Aug 21, 2026John M LeonardPresident and CEOSale22,675$12.65$286,818
Jul 22, 2026Edward J Dulac IIIEVP, Chief Financial OfficerSale8,111$11.25$91,249
Jul 2, 2026Edward J Dulac IIIEVP, Chief Financial OfficerSale4,677$18.00$84,186
Jul 1, 2026Michael P DubeVP, Chief Accounting OfficerSale2,641$16.78$44,316

Common questions

NTLA insider trading FAQ

Are NTLA insiders buying or selling?
Over the last 90 days, NTLA insiders were net sellers, reporting $0.00 of open-market purchases and $309,988 of sales.
When was the last NTLA insider purchase?
No open-market insider purchase of Intellia Therapeutics Inc stock was reported in the last 90 days.
Where does NTLA insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Intellia Therapeutics Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.